Emerging role of molecular diagnosis and personalized therapy for hepatocellular carcinoma
作者机构：Department of Hepatobiliary SurgeryEastern Hepatobiliary Surgery HospitalSecond Military Medical University(Navy Medical University)Shanghai 200438China Department of Hepatobiliary and Pancreatic SurgeryGeneral Surgery CenterFirst Hospital of Jilin UniversityChangchun 130021China
出 版 物：《iLIVER》 (国际肝胆健康（英文）)
年 卷 期：2024年第3卷第1期
页 面：38-44页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the National Natural Science Foundation of China(Nos 81972726 and 82273074 for Yang T,No.82372813 for Wang MD,Nos 82241223 and U20A20360 for Lv GY),Dawn Project Foundation of Shanghai(No.21SG36 for Yang T) Shanghai Health and Hygiene Discipline Leader Project(No.2022XD001 for Yang T) Shanghai Outstanding Academic Leader Program(No.23XD1424900 for Yang T) the Natural Science Foundation of Shanghai(No.22ZR1477900 for Wang MD) Shanghai Science and Technology Committee Rising-Star Program(No.22QA1411600 for Wang MD)
主 题：Hepatocellular carcinoma Liquid biopsy Diagnosis Immune checkpoint inhibitors Targeted therapy
摘 要：Hepatocellular carcinoma(HCC)is a prevalent malignancy worldwide,ranking as the sixth most common malignancy and the third leading cause of cancer-related *** diagnosis,limited management options,and its complex etiology contribute to the poor prognosis and high mortality *** advances in understanding the molecular mechanisms of HCC and innovations in high-throughput sequencing technologies have led to the development of molecular diagnostics and personalized therapies for this challenging *** review provides a comprehensive overview of research on the molecular diagnosis and individualized treatment for *** highlight key advances and potential future directions and discuss the application of next-generation sequencing technologies to identify and characterize genetic and epigenetic alterations in HCC *** technologies may aid in the selection of targeted therapies,prediction of treatment response,and monitoring disease ***,we explore the role of liquid biopsy in HCC diagnosis,prognosis prediction,and treatment monitoring,focusing on circulating tumor cells,circulating tumor DNA,and extracellular *** also explore the evolving landscape of personalized therapy for HCC,including targeted therapies against key oncogenic signaling pathways,immune checkpoint inhibitors,tumor-agnostic therapies,and innovative cellbased *** discuss the challenges and opportunities that lie ahead in the quest to improve HCC patient outcomes through the integration of molecular diagnostics and individualized precision *** emphasize the need for multi-interdisciplinary collaboration,refinement of predictive and prognostic biomarkers,and the development of more effective combination strategies for HCC management in the new area of precision medicine.
维普期刊数据库